[Bleomycin in Kaposi disease in a patient with heart transplantation].
BACKGROUND
Kaposi's disease is increasingly frequent in transplant recipients. The therapeutic approach in heart transplantation is not fully established.


METHODS
A 61-year-old male transplant recipient (June 1992) presented Kaposi's disease on the legs. Immunosuppressive therapy was reduced, cyclosporin by 20 p. 100, withdrawal of azathioprine and 40 p. 100 reduction in prednisone was insufficient to control the disease. Due to the extension of the lesions and the major functional handicap, bleomycin was given and led to complete regression of the lesions within 6 months.


CONCLUSIONS
This case illustrates the difficult therapeutic situation encountered in heart transplant recipients. The situation may be life-threatening with organ rejection. The first step is to reduce immunosuppressive therapy. If this is insufficient or the Kaposi is particularly aggressive, bleomycin may be used. The efficacy of bleomycin observed in our case requires confirmation in multicenter studies.
Modiano
P
P
Service de Dermatologie, Hôpital Fournier, Nancy.
Mattei
M F
MF
Reichert
S
S
Barbaud
A
A
Weber
M
M
Schmutz
J L
JL
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D016027:Heart Transplantation; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007273:Injections, Intramuscular; D007866:Leg; D008297:Male; D008875:Middle Aged; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000209:etiology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000209:etiology
D000903:Antibiotics, Antineoplastic; D001761:Bleomycin
Bléomycine dans la maladie de Kaposi chez un transplanté cardiaque.